Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Action Pharma A/S |
---|---|
Information provided by: | Action Pharma A/S |
ClinicalTrials.gov Identifier: | NCT00628264 |
The purpose of the present research study is to investigate for the first time, the safety and tolerability of infusion doses of AP214 in subjects having heart surgery such as coronary bypass graft and/or valve repair or replacement surgery. AP214, the investigational drug, is being developed to potentially prevent post-surgical kidney injury after thoracic aortic aneurysm repair.
Condition | Intervention | Phase |
---|---|---|
Cardiac Surgery Coronary Artery Bypass Grafting Valve Surgery Kidney Injury |
Drug: AP214 Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery |
Estimated Enrollment: | 75 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
AP214: Experimental |
Drug: AP214
Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
|
Placebo: Placebo Comparator |
Drug: Placebo
Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Thomas M Beaver, MD, MPH | (352) 273-5503 ext - | beavetm@surgery.ufl.edu |
Contact: Jennifer West, Nurse | (352)273-5493 | jennifer.west@surgery.ufl.edu |
United States, Florida | |
Shands Hospital at University of Florida | Recruiting |
Gainesville, Florida, United States, 32610 | |
Shands Hospital at Alachua General Hospital | Recruiting |
Gainesville, Florida, United States, 32601 |
Principal Investigator: | Thomas M Beaver, MD, MPH | Division of Thoracic and Cardiovascular Surgery , University of Florida College of Medicine |
Responsible Party: | Action Pharma A/S ( Action Pharma A/S ) |
Study ID Numbers: | AP214-CS004 |
Study First Received: | February 25, 2008 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00628264 |
Health Authority: | United States: Food and Drug Administration |
cardiac surgery coronary artery bypass grafting valve surgery acute kidney injury |